From the editorial desk

01

Intervention Profiles

27 articles

02

Clinical Trials

16 articles

03

Evidence Analysis

18 articles

04

Longevity Science

12 articles

05

Editorial

2 articles

Intervention Profiles

Vitamin D and longevity: what the VITAL trial and meta-analyses actually show

Vitamin D supplementation is one of the most-studied and most-misunderstood longevity interventions. Here is what the largest RCT and pooled meta-analyses actually found on mortality and cancer outcomes.

July 26, 2026  ·  9 min read

Intervention Profiles

Omega-3 fish oil and longevity: the VITAL and REDUCE-IT evidence

Omega-3 fatty acids show a consistent cardiovascular signal in some trials and none in others. Here is why formulation and dose explain more of the disagreement than most coverage acknowledges.

July 26, 2026  ·  8 min read

Intervention Profiles

Creatine for healthy aging: muscle, cognition, and the human evidence

Creatine has among the strongest safety and mechanistic track records of any longevity supplement. Here is what the human trial evidence shows for muscle mass, strength, and cognitive outcomes in older adults.

July 26, 2026  ·  8 min read

Intervention Profiles

Curcumin and turmeric for longevity: separating bioavailability hype from evidence

Curcumin has thousands of preclinical studies and a strong anti-inflammatory rationale, but is also one of the clearest examples of a compound whose lab promise has outpaced its human trial evidence.

July 26, 2026  ·  8 min read

Intervention Profiles

Melatonin and longevity: sleep, oxidative stress, and what's actually proven

Melatonin is marketed as both a sleep aid and an anti-aging antioxidant. Its evidence base for the two claims is very different in strength — here is what separates them.

July 26, 2026  ·  7 min read

Intervention Profiles

Green tea and EGCG for longevity: the epidemiological and mechanistic evidence

Green tea consumption is linked to lower mortality in large cohort studies. Concentrated EGCG supplements are a different exposure with a different, more concerning safety profile.

July 26, 2026  ·  7 min read

Intervention Profiles

Klotho agonists for longevity: the earliest-stage candidate in the pipeline

Klotho agonists are the earliest-stage compound class on Geroevidence's candidate list — a strong preclinical rationale with human data limited to a Phase 1b safety trial that only recently began.

July 26, 2026  ·  7 min read

Intervention Profiles

Trehalose and autophagy: an emerging longevity candidate's thin human evidence

Trehalose induces autophagy through an mTOR-independent pathway in animal models. Human longevity evidence remains almost entirely absent, making it a mechanistic candidate rather than a validated intervention.

July 26, 2026  ·  6 min read

Clinical Trials

The VITAL trial explained: what vitamin D and omega-3 did — and didn't do

Nearly 26,000 participants, over five years, testing two of the most widely used supplements in the world against cardiovascular events, cancer, and death. Here is what the trial actually found on each endpoint.

July 26, 2026  ·  9 min read

Clinical Trials

The CALERIE trial: what human caloric restriction data actually shows

Caloric restriction is the oldest and most robustly validated longevity intervention in non-human animals. CALERIE is the closest thing to a definitive human RCT — and what it found is more nuanced than "eat less, live longer."

July 26, 2026  ·  8 min read

Clinical Trials

The ABLE trial: what to expect from alpha-ketoglutarate's first real RCT

Alpha-ketoglutarate's evidence tier has been stuck at Emerging on a single uncontrolled trial. A placebo-controlled RCT is what would actually move it — here's what that trial is designed to answer.

July 26, 2026  ·  7 min read

Clinical Trials

Jardiance (empagliflozin) and longevity: reading the brand-name evidence

Jardiance is the brand name most patients search for, but the underlying trial evidence belongs to empagliflozin and the broader SGLT2 inhibitor class. Here is how to read brand-name searches against generic-class evidence.

July 26, 2026  ·  7 min read

Clinical Trials

Ozempic and Wegovy for longevity: what the brand-name semaglutide evidence shows

Ozempic and Wegovy are both semaglutide, at different doses and indications. Here is how their shared trial evidence, including SELECT, maps onto longevity-relevant claims.

July 26, 2026  ·  8 min read

Evidence Analysis

What is a hazard ratio? A physician's guide to reading longevity trial results

"HR 0.62" appears throughout Geroevidence's intervention index. Here is precisely what the number means, why the confidence interval around it matters as much as the point estimate, and where it's easy to misread.

July 26, 2026  ·  7 min read

Evidence Analysis

RCT vs. observational study: why it matters for longevity medicine claims

Vitamin D, green tea, and taurine each show strong observational associations with longevity. Only some hold up in randomized trials — here is why the study design gap explains most of the confusion.

July 26, 2026  ·  8 min read